Ticker Details
Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
IPO Date:	November 5, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$6.86B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.51 | 2.57%
Avg Daily Range (30 D):	$1.18 | 2.08%
Avg Daily Range (90 D):	$1.16 | 2.18%

Institutional Daily Volume
Avg Daily Volume:	.32M
Avg Daily Volume (30 D):	1.53M
Avg Daily Volume (90 D):	1.32M

Trade Size
Avg Trade Size (Sh.):	79
Avg Trade Size (Sh.) (30 D):	69
Avg Trade Size (Sh.) (90 D):	65

Institutional Trades
Total Institutional Trades:	3,246
Avg Institutional Trade:	$2.01M
Avg Institutional Trade (30 D):	$4.09M
Avg Institutional Trade (90 D):	$3.59M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.82M
Avg Closing Trade (30 D):	$17.37M
Avg Closing Trade (90 D):	$11.56M
Avg Closing Volume:	68.4K

News

Jun 10, 2026 @ 5:00 PM Metastatic Prostate Cancer Market Set for Robust G... Source: Delveinsight

Apr 19, 2026 @ 10:00 PM Xenon Presents Azetukalner Phase 3 X-TOLE2 Study R... Source: Xenon Pharmaceuticals Inc.

Mar 27, 2026 @ 11:03 PM Xenon Pharma Stock Up 55% as Insider Sells $78K in... Source: Jonathan Ponciano

Mar 11, 2026 @ 2:39 AM Xenon Pharmaceuticals Announces Pricing of Upsized... Source: Na

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-4.7	$-1.17	$-1.31
Diluted EPS	$-4.7	$-1.17	$-1.31
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-383.17M	$-102.3M	$-105.26M
Operating Income / Loss	$-412.66M	$-112.33M	$-109.77M
Cost of Revenue
Net Cash Flow	$429.21M	$346.7M	$94.65M
PE Ratio